^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD20 expression

i
Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Entrez ID:
Related biomarkers:
1d
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. (PubMed, J Immunother Cancer)
This biomarker analysis expands on clinical findings of odronextamab in patients with R/R B-NHL, providing verification of the suitability of CD20 as a therapeutic target, as well as evidence for potential mechanisms of action and resistance.
Journal • Immune cell
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)
|
CD20 expression
|
odronextamab (REGN1979)
3d
Studies on clinicopathological features of duodenal-type follicular lymphoma of 18 patients (PubMed, Zhonghua Xue Ye Xue Za Zhi)
Median follow-up was 12 (2-34) months. This study shows that D-FL is an indolent lymphoma, which tends to occur in the duodenum and has a good prognosis.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
|
BCL2 expression • CD20 expression • BCL2 rearrangement
23d
Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia. (PubMed, Br J Haematol)
EOI residual blasts of both CD20+ and CD20- patients had three times increased normalized CD20 expression intensity (nCD20), with the intensity among CD20- B-ALL patients reaching the pretreatment nCD20 of CD20+ B-ALL patients (4.9 vs. 3.6, p = 0.666). Rituximab can be considered in managing EOI-MRD-positive CD20- B-ALL patients as the residual blasts of these patients have quantitative and qualitative increases in CD20 expression.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Rituxan (rituximab)
24d
CD19-CD28: An affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy. (PubMed, Blood)
We developed a bispecific CD19-targeted CD28 agonist (RG6333, CD19-CD28) to enhance the efficacy of glofitamab and similar TCBs by delivering signal 2 to tumor-infiltrating T cells. CD19-CD28 distinguishes itself from the superagonistic antibody TGN1412, as its activity requires the simultaneous presence of a TCR signal and CD19 target binding...Our findings highlight CD19-CD28 as a safe and highly efficacious off-the-shelf combination partner for glofitamab, similar TCBs, and other costimulatory agonists. CD19-CD28 is currently in a Phase 1 clinical trial in combination with glofitamab.
Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Columvi (glofitamab-gxbm) • RG6333 • theralizumab (TAB08)
30d
An Evaluation of LY007 Cell Injection for r/r B-NHL (clinicaltrials.gov)
P1, N=18, Recruiting, Shanghai Longyao Biotechnology Inc., Ltd.
New P1 trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
LY007
1m
High CD204+ tumor-associated macrophage density predicts a poor prognosis in patients with clear cell renal cell carcinoma. (PubMed, J Cancer)
The presence of CD204+ TAMs in ccRCC is associated with a negative prognosis in patients. The high infiltration of CD204 promotes distant organ metastasis by aggerating Treg cells and Tex cells.
Journal
|
MSR1 (Macrophage Scavenger Receptor 1)
|
CD20 positive • CD20 expression
1m
Anti-metastatic effects of AGS-30 on breast cancer through the inhibition of M2-like macrophage polarization. (PubMed, Biomed Pharmacother)
In conclusion, this study shows that AGS-30 inhibits breast cancer growth and metastasis, probably through inhibiting M2-like macrophage polarization. Our findings suggest that AGS-30 may be a potential immunotherapeutic alternative for metastatic breast cancer.
Journal • IO biomarker • Metastases
|
IFNG (Interferon, gamma) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MMP9 (Matrix metallopeptidase 9) • STAT6 (Signal transducer and activator of transcription 6) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD20 expression • CD31 expression • MRC1 expression
1m
Trial initiation date
|
CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
CD20 expression
|
Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)
1m
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (clinicaltrials.gov)
P1, N=1, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Feb 2026 --> Mar 2024
Trial primary completion date
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
|
TP53 mutation • CD20 positive • CD20 expression
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (GS-4721)
1m
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
P2, N=349, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 expression • MYC translocation
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Mabtas (rituximab biosimilar)
1m
CD206 modulates the role of M2 macrophages in the origin of metastatic tumors. (PubMed, J Cancer)
By eliminating the expression of CD206 in M2 macrophages using siRNA, we show that the growth and metastasis of tumors was suppressed using both in vitro cell line and with experimental in vivo mouse models. In summary, we show that M2 macrophages in the blood circulation underwent a "change of loyalty" to become "cancer cells" that transformed into distal tissue metastasis, which could be suppressed by the knockdown of CD206 expression.
Journal • Metastases
|
MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • MRC1 expression
1m
Inflammatory dendritic cells restrain CD11b+CD4+ CTLs via CD200R in human NSCLC. (PubMed, Cell Rep)
Finally, we demonstrate that CD200 blockade can revive the tumor-killing role of CD11b+CD4+ CTLs and prolong the survival of tumor-bearing mice. Taken together, our study identifies CD11b+CD4+ CTLs in NSCLC with decreased cytotoxicity that can be reinvigorated by CD200 blockade, suggesting that targeting CD200 is a promising immunotherapy strategy in NSCLC.
Journal • IO biomarker
|
CD4 (CD4 Molecule) • CD200 (CD200 Molecule) • ITGAM (Integrin, alpha M) • IL1B (Interleukin 1, beta) • CD200R1 (CD200 Receptor 1)
|
CD20 expression • CD200 expression
1m
Human amniotic MSCs-mediated anti-inflammation of CD206hiIL-10hi macrophages alleviates isoproterenol-induced ventricular remodeling in mice. (PubMed, Int Immunopharmacol)
Our results demonstrated that hAMSCs effectively alleviated ISO-induced cardiac hypertrophy and fibrosis, and improved the cardiac functions in mice, and the underlying mechanisms might be related to inhibiting the inflammation and fibrosis during the ventricular remodeling through promoting the polarization of CD206hiIL-10hi macrophages in heart tissues. Our study strongly suggested that by taking the advantages of the potent immunosuppressive and anti-inflammatory effects, hAMSCs may provide an alternative therapeutic approach for prevention and treatment of VR clinically.
Preclinical • Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
CD20 expression • IL6 expression • MRC1 expression
1m
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma. (PubMed, MAbs)
Furthermore, preclinical studies have demonstrated that CC-96673 exhibits acceptable pharmacokinetic properties with a favorable toxicity profile in non-human primates. Collectively, these findings define CC-96673 as a promising CD47 × CD20 bispecific antibody that selectively destroys CD20+ cancer cells via enhanced phagocytosis and other effector functions.
Journal • IO biomarker
|
SIRPA (Signal Regulatory Protein Alpha)
|
CD20 expression
2ms
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (clinicaltrials.gov)
P1, N=1, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=76 --> 1 | Trial completion date: Jun 2028 --> Feb 2027
Enrollment closed • Enrollment change • Trial completion date
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
|
TP53 mutation • CD20 positive • CD20 expression
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (GS-4721)
2ms
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
P2, N=159, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed
Trial completion
|
CD20 expression
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Zevalin (ibritumomab tiuxetan)
2ms
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CD20 expression
|
cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • dexamethasone injection • methotrexate IV
2ms
Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing. (PubMed, Br J Dermatol)
In patients with MM that harbour a CD20+ subpopulation, combined therapy with BRAF inhibitor and anti-CD20 antibody could potentially kill residual MM cells and prevent disease recurrence.
Journal
|
FOXM1 (Forkhead Box M1)
|
BRAF mutation • CD20 expression • MS4A1 mutation
2ms
Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms. (PubMed, BMC Pulm Med)
In stage IA NSCLC, a low concentration of IFN-γ promotes the polarization of TAMs to the M2 phenotype in the TME model by upregulating the expression of IDO1, promoting the viability of cancer cells, inhibiting the viability of T cells and NK cells, and thus establishing an immune microenvironment conducive to tumor progression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
|
BCL2 expression • CD20 expression • IDO1 expression • IFNG expression • BAX expression • CD163 expression • MRC1 expression
2ms
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study. (PubMed, Cancers (Basel))
Discordant cases by immunophenotype and/or morphology did not identify specific prognostic groups. Whether-in the era of molecular markers used as prognostic indicators-it does make sense to focus on morphology and immunophenotype features in CLL is still matter of debate needing further research.
Retrospective data • Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • ITGA4 (Integrin, alpha 4)
|
CD20 positive • CD20 expression
2ms
NP39488: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=280, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2024 --> Sep 2026 | Trial primary completion date: Nov 2024 --> Sep 2026 | Recruiting --> Active, not recruiting
Enrollment closed • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
2ms
Plasmablastic Lymphoma. A State-of-the-Art Review: Part 1-Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Prognostic Factors, and Special Populations. (PubMed, Mediterr J Hematol Infect Dis)
This condition is frequently associated with infections caused by the Epstein-Barr virus and genetic alterations involving the MYC gene. Despite advances in our comprehension of this disease, the prognosis remains dismal, resulting in a low overall survival rate, although recent reports suggest an apparent tendency towards substantial improvement.
Review • Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • PAX5 (Paired Box 5) • SDC1 (Syndecan 1) • IRF4 (Interferon regulatory factor 4) • PRDM1 (PR/SET Domain 1) • XBP1 (X-box-binding protein 1)
|
ALK positive • CD20 expression • CD20 negative
3ms
IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS. (PubMed, Exp Oncol)
Our data confirmed a reduced CD20 expression in CLL patients with NOTCH1 and SF3B1 mutations. In addition, an approach was proposed to identify high-risk CLL patients for prediction of such mutations: previously untreated CLL patients at advanced Binet - Rai stages (BII, CIII, CIV) with a reduced number of double-positive CD20+CD5+ cells in peripheral blood and/or low iMFI of CD20+ cells.
Journal
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • CD5 (CD5 Molecule)
|
TP53 mutation • NOTCH1 mutation • SF3B1 mutation • CD20 expression • NOTCH1 expression
3ms
Clinical and pathological characteristics and prognosis analysis of gray zone lymphoma (PubMed, Zhonghua Yi Xue Za Zhi)
GZL may be more sensitive to DLBCL-like intensive immune regimens. Sequential ASCT for consolidation can reduce the risk of relapse.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • FUT4 (Fucosyltransferase 4)
|
TNFRSF8 expression • CD20 expression
3ms
Clinicopathological features of intravascular large B-cell lymphoma and collision tumors of five cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
Collision tumors of IVLBCL are extremely rare. A better understanding of IVLBCL would help pathologists avoid misdiagnoses.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • PAX5 (Paired Box 5) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • VIM (Vimentin) • MME (Membrane Metalloendopeptidase) • PAX8 (Paired box 8)
|
PD-L1 negative • MYC expression • CD20 expression • CD5 positive • VIM expression
3ms
Primary cardiac large B cell lymphoma. (PubMed, BMJ Case Rep)
She was treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab chemotherapy. Rituximab was discontinued owing to largely absent CD20 expression. Interim positron emission tomography-CT after three cycles revealed a complete response, and the patient completed six cycles of therapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase)
|
MYC rearrangement + BCL6 rearrangement • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
3ms
Trial completion date • Trial primary completion date • Combination therapy
|
ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
ALK positive • BCL2 expression • MYC expression • CD20 expression • BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine
3ms
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=178, Active, not recruiting, Gilead Sciences | Phase classification: P1b/2 --> P1/2 | Trial completion date: Aug 2024 --> May 2024 | Trial primary completion date: Aug 2024 --> May 2024
Phase classification • Trial completion date • Trial primary completion date • Combination therapy
|
CD20 expression
|
gemcitabine • Rituxan (rituximab) • oxaliplatin • magrolimab (GS-4721)
4ms
Medrysone promotes corneal injury repair by promoting M2-like polarization of macrophages. (PubMed, BMC Ophthalmol)
Our study suggest that Medrysone promotes corneal injury repair by inducing the M2 polarization of macrophages, providing a theoretical basis for the application of Medrysone in the treatment of corneal injury.
Journal
|
CCL2 (Chemokine (C-C motif) ligand 2) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • MRC1 expression
4ms
New P1/2 trial
|
CD19 (CD19 Molecule)
|
CD20 expression • CD19 expression
4ms
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy (clinicaltrials.gov)
P2, N=67, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial primary completion date: Sep 2023 --> Jan 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
4ms
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. (PubMed, Blood)
This study expands knowledge about the occurrence of target antigen loss after anti-CD20 therapeutics to CD20-targeting bispecific antibodies and elucidates the underlying mechanisms for reduced CD20 expression at disease progression that may be generalizable to other anti-CD20 targeting agents. These results also establish the utility of readily-available IHC staining for CD20 as a tool to inform clinical decisions.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Lunsumio (mosunetuzumab-axgb)
4ms
Acacetin protects against sepsis-induced acute lung injury by facilitating M2 macrophage polarization via TRAF6/NF-κB/COX2 axis. (PubMed, Innate Immun)
And TRAF6 could offset the impact of acacetin. This study demonstrated that acacetin could prevent sepsis-induced ALI by facilitating M2 macrophage polarization via TRAF6/NF-κB/COX2 axis.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • MPO (Myeloperoxidase) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II) • TRAF6 (TNF Receptor Associated Factor 6)
|
CD20 expression • PTGS2 expression • IL6 expression • MRC1 expression
4ms
Evaluation of the Potential Impact on Pharmacokinetics of Various Cytochrome P450 Substrates of increasing IL-6 Levels following administration of the T-cell bispecific engager Glofitamab. (PubMed, CPT Pharmacometrics Syst Pharmacol)
It is recommended that there are no restrictions on concomitant treatment with any other drugs. Consideration may be given for potential DDI during the first cycle in patients who are receiving concomitant CYP substrates with a narrow therapeutic index via monitoring for toxicity or for drug concentrations.
PK/PD data • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
IL6 elevation • CD20 expression
|
Columvi (glofitamab-gxbm)
4ms
Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells (ASH 2023)
Co-culture of Jurkat-Lucia cells for 6 hours with the anti-CD20 mAb rituximab and MEC1 or MEC1-ROR1 cells induced Jurkat-Lucia cells to express a luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements; this endowed the Jurkat-Lucia cells with high luminescence activity that was not observed in co-cultures of EC and TC without added mAb. ROR1 + CLL cells harboring del(17p) or mutations in TP53 (del(17p)/m TP53) and/or that were resistant to targeted therapies (e. g. , inhibitors of BTK or BCL2), were as susceptible to GE-zilovertamab-directed ADCC as were CLL cells without del(17p)/m TP53 from patients who had not had prior therapy. These data demonstrate that GE-zilovertamab can direct high-level ADCC lysis of ROR1-expressing neoplastic cells with greater activity than zilovertamab, encouraging development of clinical studies to evaluate GE-zilovertamab for therapy of patients with CLL or other ROR1-positive cancers.
IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • ADAM17 (ADAM Metallopeptidase Domain 17) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
TP53 mutation • ROR1 expression • CD20 expression • ROR1 positive
|
Rituxan (rituximab) • zilovertamab (UC-961)
4ms
Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion (ASH 2023)
Rituximab combined with CAR-T therapy was effective for improving the long-term outcome of B-ALL patients who have failed multiple lines of therapy. In vitro, we observed that rituximab potentially improved CAR-T efficacy by sensitizing Leukemia Cells to CAR T-mediated cytotoxicity and reducing CAR-T exhaustion.
Clinical • Clinical data • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2 (Interleukin 2)
|
CD20 positive • CD20 expression • LAG3 expression
|
Rituxan (rituximab)
4ms
Exploring BiTE-Integrated CAR T-Cell Therapy to Overcome Tumor Antigen Escape and Reinforce CAR-T Therapy in Mantle Cell Lymphoma (ASH 2023)
The anti-lymphoma efficacy of engager-CAR T cell therapy will be further evaluated in our well-established unique PDX model for MCL. In summary, we have successfully generated a CD20-directed bispecific T-cellengaging antibody and CD20-BiTE engager-T cells that could be combined with CAR T cell therapy, which was demonstrated effective in overcoming tumor antigen escape and resistance to current CD19-CAR T cell therapy in MCL.
CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • GZMB (Granzyme B)
|
CD20 positive • CD20 expression • CD19 expression • IL2RA expression
4ms
A Unique Case of Large Pelvic Non-Hodgkin Lymphoma (ASH 2023)
The patient was discharged for outpatient follow-up with oncology with a treatment plan of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) administered every 3 weeks, omitting rituximab during the first cycle. Understanding the immunophenotypic characteristics of the tumor is essential for tailoring effective therapeutic strategies. This unique case sheds light on the need for further research and evidence-based guidelines for managing NHL in uncommon anatomical locations, promoting better patient outcomes and quality of life.
Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD20 expression • CD19 expression
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
4ms
Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma (ASH 2023)
It is recently available in China and approved in combination with Bendamustine and Rituximab for r/r DLBCL. gov (NCT05940051) . We illustrated the flowchart of our study in Figure 2.
Clinical • IO biomarker
|
CD79B (CD79b Molecule)
|
CD20 expression
|
Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine • Polivy (polatuzumab vedotin-piiq)
4ms
Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell Lymphoma (ASH 2023)
We find that CD20 expression before treatment is an important prognostic factor, as patients with lymphomas with weak CD20 expression yield significantly poorer responses and decreased overall survival. Additionally, we find that BCL6 rearrangement is associated with superior overall survival in patients treated with CD3XCD20 bispecific antibodies.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
|
CD20 expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative • BCL6 positive
4ms
The KIR-HLA-CD16a Immunogenetic Profile Influences NK Cell-Mediated ADCC and Response to Rituximab Therapy in B-Cell Lymphomas (ASH 2023)
These findings suggest a potential role for immunogenotyping in B-cell lymphomas treated with Rituximab. Additionally, the presence of the shared F c receptor domain opens the possibility of applying this framework towards predicting NK cell responses to antibody therapies in other diseases.
IO biomarker
|
FCGR3A (Fc Fragment Of IgG Receptor IIIa) • NKG2D (killer cell lectin like receptor K1)
|
CD20 expression
|
Rituxan (rituximab)
4ms
Anti-inflammatory mechanisms in cancer research: Characterization of a distinct M2-like macrophage model derived from the THP-1 cell line. (PubMed, Cancer Med)
The THP-1-derived M2 macrophage based on a standardized cell line model represents a distinct anti-inflammatory TAM-like phenotype with an M2a subtype profile. This model may provide a basis for in vitro investigation of functional mechanisms in a variety of anti-inflammatory settings, particularly colon cancer development.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 expression • CXCL8 expression • MRC1 expression